IRLAB Therapeutics: Update on pirepemat PD-Falls study - ABG

More baseline falls vs. expected implies higher likelihood of effect
New guidance: completion of study enrolment in Q3'24e (Q1'24 prev.)
Q4'23 report tomorrow at 07:00 CET


Increased fall rate and lower drop out in React-PD

Today IRLAB released an update on Ph 2b study React-PD evaluating the potential of pirepemat in PD-Falls, including new details on the recruited patient population in the study, as well an update on timelines. Regarding the details on the study population, IRLAB communicated that at baseline, patients fall two to three times more often than previously anticipated, with individual fall rates stable during the one-month run-in period ahead of treatment start. We see this as positive for the study, since a higher baseline fall-rate could increase the probability of detecting a potential treatment-dependent effect on falls. Additionally, IRLAB communicated that drop-outs have been lower than expected leading to the decision to initiate discussions about submission of a study amendment to reduce the number of patients, while maintaining the study's power to detect differences in fall rates.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/irlab-therapeutics/Equity-research/2024/2/irlab-therapeutics---update-on-pirepemat-pd-falls-study/